Cholesterol lowering for secondary prevention: What statin dose should we use?

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 615-627

  Josan, Kiranbir ^a   McAlister, Finlay A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Dosing; Efficacy; Safety; Secondary prevention; Statins

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY INTIMA PROLIFERATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DATA ANALYSIS; DEATH; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INDIVIDUALIZATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORTALITY; MYOPATHY; OUTCOME ASSESSMENT; PATIENT INFORMATION; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SECONDARY PREVENTION; SIDE EFFECT; STROKE; TREATMENT OUTCOME;

CHOLESTEROL; CONTROLLED CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 36148946710     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. 2002. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA, 288:2998-3007.
2. Bays H. 2006. Statin safety: An overview and assessment of the data - 2005. Am J Cardiol, 97(Suppl):6C-26C.
3. Bissonnette S, Habib R, Sampalis F, et al. 2006. Efficacy and tolerability of ezetimibe 10 mg/day co administered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study - the Ezetrol Add-On Study. Can J Cardiol, 22:1035-44.
4. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. 2005, JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart, 91(Suppl 5):v1-52.
5. Brown BG, Zhao XQ, Chait A, et al. 2001. Simvastatin and niacin, antioxidant vitamins, or their combination for the prevention of coronary disease. N Engl J Med, 345:1583-92.
6. Cannon CP, Braunwald E, McCabe CH, et al. 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 350:1495-504.
7. Charles EC, Olson KL, Sandhoff BG, et al. 2005. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med, 118:618-24.
8. Chen Z, Peto R, Collins R, et al. 1991. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ, 303:276-82.
9. Cholesterol Treatment Trialists' Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366:1267-78.
10. Colhoun HM, Betteridge DJ, Durrington PN, et al. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 364:685-96.
11. Davignon J. 2004. Beneficial cardiovascular pleiotropic effects of statins. Circulation, 109:39-43.
12. Deedwania P, Barter P, Carmena R, et al. 2006. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets Study. Lancet, 368:919-28.
13. de Lemos JA, Blazing MA, Wiviott SD, et al. 2004. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA, 292:1307-16.
14. Downs JR, Clearfield M, Weis S, et al. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA, 279:1615-22.
15. GISSI Prevenzione Investigators (Grappo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). 2000. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J, 1:810-20.
16. Grundy SM, Cleeman JI, Merz CN, et al. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 110:227-39.
17. Grundy SM. 2005. The issue of statin safety. Where do we stand? Circulation, 111:3016-9.
18. Hayward RA, Hofer TP, Vijan S. 2006. Narrative review: Lack of evidence for recommended low-density lipoprotem treatment targets: A solvable problem. Ann Intern Med, 145:520-30.
19. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
20. Holdaas H, Fellstrom B, Jardine AG, et al. 2003. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet, 361:2024-31.
21. Jadad AR, Moore RA, Carroll D, et al. 1996. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials, 17:1-12.
22. Jones PH, Davidson MH, Stein EA, et al. STELLAR study group. 2003. Comparison and efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses. Am J Cardiol, 92:152-60.
23. Josan K, Majumdar SR, McAlister FA. 2007. The efficacy and safety of intensive statin therapy: A meta-analysis of randomized trials. CMAJ, (under review).
24. Kashani A, Phillips CO, Foody JM, et al. 2006. Risks associated with statin therapy. A systematic overview of randomized clinical trials. Circulation, 114:2788-97.
25. Khan NA, McAlister FA, Rabkin SW, et al. 2006. The 2006 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 2 - Therapy. Can J Cardiol, 22:583-93.
26. LaRosa JC, Grundy SM, Waters DD, et al. Treating to new targets (TNT) Investigators. 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 352:1425-35.
27. Law MR, Wald NJ, Rudnicka AR. 2003. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 326:1423.
28. Liem AH, van Boven AJ, Veeger NJ, et al. Fluvastatin On Risk Diminishment after Acute myocardial infarction (FLORIDA) study group. 2002. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J, 23:1931-7.
29. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 339:1349-57.
30. Mann SJ. 2006. Letter to the editor. JAMA, 295:2477-8.
31. Nissen SE, Tuzcu EM, Schoenhagen P, et al. 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized control trial. JAMA, 291:1071-80.
32. Nissen SE. 2006. High-dose statins in acute coronary syndromes. Not just lipid levels. JAMA, 292:1365-7.
33. O'Keefe JH, Cordain L, Harris WH, et al. 2004. Optimal low-density lipoprotein is 50 to 70 mg/dl. Lower is better and physiologically normal. J Am Coll Cardiol, 43:2142-6.
34. Pablos Mendez A, Barr RG, Shea S. 1998. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA, 279:222-5.
35. Padwal R, Straus SE, McAlister FA. 2001. Cardiovascular risk factors and their impact on the decision to treat hypertension: an evidence-based review. BMJ, 322:977-80.
36. Pasternak RC, Smith SC, Bairey-Merz CN, et al. 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol, 40:567-72.
37. Pedersen TR, Faergeman O, Kastelein JJ, et al. 2005. High-dose atorvastatin vs usual-dose siravastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA, 294:2437-45.
38. Pitt B, Waters D, Brown WV, et al. 1999. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med, 341:70-6.
39. The Post Coronary Artery Bypass Graft Trial Investigators. 1997. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med, 336:153-62.
40. Robinson JG, Smith B, Maheshwari N, et al. 2005. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol, 46:1855-62.
41. Sacks FM, Pfeffer MA, Moye LA, et al; for the Cholesterol and Recurrent Events Trial Investigators. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 335:1001-9.
42. Scandinavian Simvastatin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344:1383-9.
43. Schwartz GG, Olsson AG, Ezekowitz MD, et al. 2001. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 285:1711-8.
44. Serruys PW, de Feyter P, Macaya C, et al. 2002. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA, 287:3215-22.
45. Sever PS, Dahlof B, Poulter NR, et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 361:1149-58.
46. Shepherd J, Blauw GJ, Murphy MB, et al. 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360:1623-30.
47. Shepherd J, Cobbe SM, Ford I, et al. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med, 333:1301-7.
48. Smilde TJ, van Willsen S, Wollersheim H, et al. 2001. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet, 357:577-81.
49. Stein E, Stender S, Mata P, et al. 2004. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J, 148:447-55.
50. Stone PH, Lloyd-Jones DM, Kinlay S, et al. 2005. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the treatment of myocardial ischemia study. Circulation, 111:1747-55.
51. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. 2006. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 355:549-59.
52. Taylor AJ, Kent SM, Flaherty PJ, et al. 2002. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation, 106:2055-60.
53. Thompson PD, Clarkson P, Karas RH. 2003. Statin-associated myopathy. JAMA, 289:1681-90.
54. Verschuren WM, Jacobs DR, Bloemberg BP, et al. 1995. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five year follow-up of the seven countries study. JAMA, 274:131-6.
55. Wiviott SD, Cannon CP, Morrow DA, et al. 2005. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy. A PROVE-IT TIMI 22 Substudy. J Am Coll Cardiol, 46:1411-6.